Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

No more finger pricks? study tests CGM for faster healing of diabetic foot ulcers

NCT ID NCT06054659

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether using a continuous glucose monitor (CGM) instead of standard fingerstick testing helps people with type 2 diabetes heal foot ulcers faster. 116 adults who had been hospitalized for a diabetic foot ulcer were randomly assigned to use either a CGM or their usual fingerstick method. The researchers tracked wound healing rates and time to healing, as well as quality of life. The goal was to see if CGM, which provides constant glucose readings without fingersticks, could improve blood sugar control and wound recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Real-time continuous glucose monitoring (CGM) device
What this could lead to
If successful, this could show that CGM helps diabetic foot ulcers heal faster and reduces the need for painful fingerstick tests.
What could go wrong
This is a small, completed study with 116 participants, so results may not apply to all patients. CGM devices can be less accurate than fingersticks in some cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

116 people

The number who actually took part.

Started

Feb 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 and over with type 2 diabetes admitted to the hospital with diabetic foot ulceration with or without infection (cellulitis or osteomyelitis) * HbA1c \>= 8.0% at the time of enrollment * Treatment of diabetic foot ulcer with medical management and/or a single toe amputation * Patients with prior amputation at or below the ankle may be enrolled if they develop an ulceration in the foot that is not felt to be a surgical wound from prior amputation, defined as a healed surgical site for at least 6 weeks after the surgery before the onset of the new ulceration * Wound, Ischemia, foot Infection (WIfI) score of 1-3 * Duration of DFU less than 1 year * Able and willing to use continuous glucose monitoring technology independently or with the assistance of a close relative or caretaker Exclusion Criteria: * Age \< 18 years * Homelessness or anticipated to have unstable housing after discharge * A WIfI score of 4, denoting a very high risk for major amputation (above or below the knee) and very low odds of healing within 12 months * Any amputation more extensive than just a single toe during index hospitalization * Patients with type 1 diabetes * Participants enrolled in another interventional clinical trial (including during the run-in period). * Inability to participate in the informed consent process for any reason * Female subjects who are pregnant or breastfeeding at the time of enrollment in the study * Subjects planning to use CGM technology independent of the study following discharge * Subjects unwilling to wear a CGM device and/or monitor blood glucose with FBG

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes type 2 with diabetic ulcer of toe, skin breakdown are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Emory Decatur Hospital

    Decatur, Georgia, 30033, United States

  • Grady Health System

    Atlanta, Georgia, 30303, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.